• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

HMG-CoA还原酶抑制剂与P-糖蛋白调节

HMG-CoA reductase inhibitors and P-glycoprotein modulation.

作者信息

Bogman K, Peyer A K, Török M, Küsters E, Drewe J

机构信息

Department of Clinical Pharmacology and Toxicology, University Hospital/Kantonsspital, Basel, Switzerland.

出版信息

Br J Pharmacol. 2001 Mar;132(6):1183-92. doi: 10.1038/sj.bjp.0703920.

DOI:10.1038/sj.bjp.0703920
PMID:11250868
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1572659/
Abstract
  1. Five 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins), (e.g. atorvastatin, fluvastatin, lovastatin, pravastatin and simvastatin), were investigated for their ability to reverse P-glycoprotein (P-gp) mediated rhodamine 123 (R123) transport in a murine monocytic leukaemia cell line that over-expresses the multi-drug resistance protein 1a/b (mdr1a/1b). 2. P-gp modulation was studied by a fluorimetric assay and confocal microscopy by means of R123 efflux and uptake experiments, respectively. 3. Atorvastatin acid, methyl ester and lactone, lovastatin lactone and simvastatin lactone inhibited R123 transport in a concentration-dependent manner. Lovastatin acid, simvastatin acid, fluvastatin and pravastatin did not show a significant inhibition of the R123 transport in our cell system. Atorvastatin methyl ester and lactone showed the highest affinities for P-gp and results were comparable for both methods. 4. In conclusion, monitoring of R123 transport in living cells by confocal microscopy in addition to fluorimetric assay is a sensitive tool to study P-gp affinity in drug screening that is especially useful for early phases of drug development.
摘要
  1. 研究了五种3-羟基-3-甲基戊二酰辅酶A(HMG-CoA)还原酶抑制剂(他汀类药物),即阿托伐他汀、氟伐他汀、洛伐他汀、普伐他汀和辛伐他汀,在过表达多药耐药蛋白1a/1b(mdr1a/1b)的小鼠单核细胞白血病细胞系中逆转P-糖蛋白(P-gp)介导的罗丹明123(R123)转运的能力。2. 分别通过R123外排和摄取实验,利用荧光测定法和共聚焦显微镜研究P-gp调节。3. 阿托伐他汀酸、甲酯和内酯、洛伐他汀内酯和辛伐他汀内酯以浓度依赖性方式抑制R123转运。洛伐他汀酸、辛伐他汀酸、氟伐他汀和普伐他汀在我们的细胞系统中未显示出对R123转运的显著抑制作用。阿托伐他汀甲酯和内酯对P-gp表现出最高亲和力,两种方法的结果具有可比性。4. 总之,除荧光测定法外,通过共聚焦显微镜监测活细胞中的R123转运是一种在药物筛选中研究P-gp亲和力的灵敏工具,对药物开发的早期阶段特别有用。

相似文献

1
HMG-CoA reductase inhibitors and P-glycoprotein modulation.HMG-CoA还原酶抑制剂与P-糖蛋白调节
Br J Pharmacol. 2001 Mar;132(6):1183-92. doi: 10.1038/sj.bjp.0703920.
2
Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1.3-羟基-3-甲基戊二酰辅酶A还原酶抑制剂与ABCB1、ABCC2和OATP1B1的差异相互作用
Drug Metab Dispos. 2005 Apr;33(4):537-46. doi: 10.1124/dmd.104.002477. Epub 2004 Dec 22.
3
Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of losartan and its main metabolite EXP-3174 in rats: possible role of CYP3A4 and P-gp inhibition by HMG-CoA reductase inhibitors.HMG-CoA 还原酶抑制剂对洛沙坦及其主要代谢物 EXP-3174 在大鼠体内药代动力学的影响:HMG-CoA 还原酶抑制剂对 CYP3A4 和 P-糖蛋白的抑制作用可能起作用。
Pharmacology. 2011;88(1-2):1-9. doi: 10.1159/000328773. Epub 2011 Jun 25.
4
Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.葡萄柚汁会增加阿托伐他汀的血清浓度,而对普伐他汀没有影响。
Clin Pharmacol Ther. 1999 Aug;66(2):118-27. doi: 10.1053/cp.1999.v66.100453001.
5
Differential interactions between statins and P-glycoprotein: implications for exploiting statins as anticancer agents.他汀类药物与 P-糖蛋白的差异相互作用:利用他汀类药物作为抗癌药物的意义。
Int J Cancer. 2010 Dec 15;127(12):2936-48. doi: 10.1002/ijc.25295.
6
Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: an in vitro investigation with human liver preparations.米贝拉地尔与HMG-CoA还原酶抑制剂之间的代谢相互作用:用人肝制剂进行的体外研究。
Br J Clin Pharmacol. 1999 Mar;47(3):291-8. doi: 10.1046/j.1365-2125.1999.00903.x.
7
Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins).3-羟基-3-甲基戊二酰辅酶A还原酶抑制剂(他汀类药物)的代谢及药物相互作用
Eur J Clin Pharmacol. 2001 Aug;57(5):357-64. doi: 10.1007/s002280100329.
8
pH-sensitive interaction of HMG-CoA reductase inhibitors (statins) with organic anion transporting polypeptide 2B1.HMG-CoA 还原酶抑制剂(他汀类药物)与有机阴离子转运多肽 2B1 的 pH 敏感性相互作用。
Mol Pharm. 2011 Aug 1;8(4):1303-13. doi: 10.1021/mp200103h. Epub 2011 Jul 11.
9
HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein.HMG-CoA还原酶抑制剂(他汀类药物)被表征为P-糖蛋白的直接抑制剂。
Pharm Res. 2001 Jun;18(6):800-6. doi: 10.1023/a:1011036428972.
10
Effects of acid and lactone forms of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on the induction of MDR1 expression and function in LS180 cells.3-羟基-3-甲基戊二酰辅酶A还原酶抑制剂的酸形式和内酯形式对LS180细胞中多药耐药蛋白1(MDR1)表达及功能诱导的影响
Eur J Pharm Sci. 2009 May 12;37(2):126-32. doi: 10.1016/j.ejps.2009.01.009. Epub 2009 Feb 5.

引用本文的文献

1
Determination of the latent geometry of atorvastatin pharmacokinetics by transfer entropy to identify bottlenecks.通过转移熵确定阿托伐他汀药代动力学的潜在几何结构以识别瓶颈
BMC Pharmacol Toxicol. 2025 Jun 25;26(Suppl 1):123. doi: 10.1186/s40360-025-00948-6.
2
Emerging Multifunctional Biomaterials for Addressing Drug Resistance in Cancer.用于解决癌症耐药性的新型多功能生物材料
Biology (Basel). 2025 May 2;14(5):497. doi: 10.3390/biology14050497.
3
The Association Between Statin Drugs and Rhabdomyolysis: An Analysis of FDA Adverse Event Reporting System (FAERS) Data and Transcriptomic Profiles.他汀类药物与横纹肌溶解症之间的关联:对美国食品药品监督管理局不良事件报告系统(FAERS)数据和转录组学图谱的分析
Genes (Basel). 2025 Feb 21;16(3):248. doi: 10.3390/genes16030248.
4
MiRNAs function in the development of resistance against doxorubicin in cancer cells: targeting ABC transporters.微小RNA在癌细胞对多柔比星耐药性发展中的作用:靶向ATP结合盒转运蛋白
Front Pharmacol. 2024 Nov 29;15:1486783. doi: 10.3389/fphar.2024.1486783. eCollection 2024.
5
Muscular toxicity of colchicine combined with statins: a real-world study based on the FDA adverse event reporting system database from 2004-2023.秋水仙碱与他汀类药物联用的肌肉毒性:一项基于2004年至2023年美国食品药品监督管理局不良事件报告系统数据库的真实世界研究。
Front Pharmacol. 2024 Jul 26;15:1418498. doi: 10.3389/fphar.2024.1418498. eCollection 2024.
6
Tetrandrine for Targeting Therapy Resistance in Cancer.汉防己甲素靶向治疗癌症耐药。
Curr Top Med Chem. 2024;24(12):1035-1049. doi: 10.2174/0115680266282360240222062032.
7
The Role of CYPs and Transporters in the Biotransformation and Transport of the Anti-hepatitis C Antiviral Agents Asunaprevir, Daclatasvir, and Beclabuvir: Impact of Liver Disease, Race and Drug-drug Interactions on Safety and Efficacy.细胞色素 P450 酶和转运体在抗丙型肝炎抗病毒药物asunaprevir、daclatasvir 和 beclabuvir 的生物转化和转运中的作用:肝脏疾病、种族和药物相互作用对安全性和疗效的影响。
Curr Drug Metab. 2024;25(2):96-109. doi: 10.2174/0113892002288832240213095622.
8
Mechanisms and Clinical Significance of Pharmacokinetic Drug Interactions Mediated by FDA and EMA-approved Hepatitis C Direct-Acting Antiviral Agents.FDA 和 EMA 批准的丙型肝炎直接抗病毒药物介导的药代动力学药物相互作用的机制和临床意义。
Clin Pharmacokinet. 2023 Oct;62(10):1365-1392. doi: 10.1007/s40262-023-01302-x. Epub 2023 Sep 20.
9
Effects of Simvastatin on Pharmacokinetics and Anticoagulant Effects of Dabigatran in Healthy Subjects.辛伐他汀对健康受试者中达比加群药代动力学及抗凝作用的影响
Pharmaceuticals (Basel). 2023 Feb 27;16(3):364. doi: 10.3390/ph16030364.
10
Utilization of a nanostructured lipid carrier encapsulating pitavastatin- oil for enhancing cytotoxicity against the gingival carcinoma HGF-1 cell line.利用纳米结构脂质载体包埋匹伐他汀-油,增强对牙龈癌细胞系 HGF-1 的细胞毒性。
Drug Deliv. 2023 Dec;30(1):83-96. doi: 10.1080/10717544.2022.2155269.

本文引用的文献

1
HIV protease inhibitor ritonavir: a more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833.HIV蛋白酶抑制剂利托那韦:一种比环孢素类似物SDZ PSC 833更强效的P-糖蛋白抑制剂。
Biochem Pharmacol. 1999 May 15;57(10):1147-52. doi: 10.1016/s0006-2952(99)00026-x.
2
Drug Interactions: A Source Book of Adverse Interactions, Their Mechanisms, Clinical Importance and Management.《药物相互作用:不良相互作用、作用机制、临床重要性及处理方法资料手册》
Ann Intern Med. 2000 Nov 7;133(9):760. doi: 10.7326/0003-4819-133-9-200011070-00041.
3
Mibefradil is a P-glycoprotein substrate and a potent inhibitor of both P-glycoprotein and CYP3A in vitro.米贝拉地尔是一种P-糖蛋白底物,在体外是P-糖蛋白和CYP3A的强效抑制剂。
Drug Metab Dispos. 2000 Aug;28(8):895-8.
4
In vitro flow cytometry method to quantitatively assess inhibitors of P-glycoprotein.体外流式细胞术法定量评估P-糖蛋白抑制剂
Drug Metab Dispos. 2000 May;28(5):522-8.
5
Atorvastatin transport in the Caco-2 cell model: contributions of P-glycoprotein and the proton-monocarboxylic acid co-transporter.阿托伐他汀在Caco-2细胞模型中的转运:P-糖蛋白和质子-单羧酸共转运体的作用
Pharm Res. 2000 Feb;17(2):209-15. doi: 10.1023/a:1007525616017.
6
Development of an immobilized P-glycoprotein stationary phase for on-line liquid chromatographic determination of drug-binding affinities.用于在线液相色谱法测定药物结合亲和力的固定化P-糖蛋白固定相的研制。
J Chromatogr B Biomed Sci Appl. 2000 Feb 28;739(1):33-7. doi: 10.1016/s0378-4347(99)00384-9.
7
The interaction of diltiazem with simvastatin.地尔硫䓬与辛伐他汀的相互作用。
Clin Pharmacol Ther. 2000 Mar;67(3):267-74. doi: 10.1067/mcp.2000.104609.
8
Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo.人类多药耐药基因的功能多态性:多个序列变异以及一个等位基因与体内P-糖蛋白表达和活性的相关性
Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3473-8. doi: 10.1073/pnas.97.7.3473.
9
Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: linking in vitro with in vivo information.米贝拉地尔与HMG-CoA还原酶抑制剂之间的代谢相互作用:将体外研究与体内信息相联系。
Br J Clin Pharmacol. 2000 Jan;49(1):87-90.
10
New insights into the pharmacodynamic and pharmacokinetic properties of statins.他汀类药物药效学和药代动力学特性的新见解。
Pharmacol Ther. 1999 Dec;84(3):413-28. doi: 10.1016/s0163-7258(99)00045-5.